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of opportunity’’ that could represent a chance to intervene 
earlier in the disease course, thus potentially preventing 
organ damage.
The definition of Very early SSc has been proposed as a 
state characterized by RP, puffy fingers, disease-specific 
autoantibodies, and pathognomonic microvascular alte-
rations at capillaroscopy, without skin and internal organ 
involvement. In patients with the above symptoms further 
investigations such as esophageal manometry, B-mode ec-
hocardiography, and lung function tests are recommended 
to detect preclinical alterations of internal organs in SSc.
Recently, new classification criteria have been proposed 
with the goal to identify patients in the earliest phase of 
the disease. However, as predictors of the future course of 
the disease are still unknown, patients must be followed up 
regularly, even though the ideal frequency of visits has not 
yet been established.
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Abstract
Systemic sclerosis (SSc) is a chronic autoimmune disease, 
characterized by a high level of clinical heterogeneity and 
associated with a high morbidity along with the highest 
disease-specific mortality of all autoimmune connective 
tissue diseases. SSc is quite easy to diagnose in the advan-
ced phase, i.e., when it has already evolved to obliterative 
vasculopathy and skin and internal organ fibrosis, but 
it is difficult to establish a diagnosis in the early phase. 
This limits the possibility to start early treatment, as well 
as the potential for prevention of disease evolution and 
tissue damage. Raynaud’s phenomenon (RP) has been 
proposed as one of the defining clinical features for the 
diagnosis of “early” SSc, so that particular attention sho-
uld be paid to this symptom, even in the absence of other 
signs of the disease. Based on previous diagnostic crite-
ria, the diagnosis of SSc can be delayed for several years 
after the onset of RP, and even after the onset of the first 
non-RP symptom.
This time gap between symptoms and diagnosis, mainly 
based on dermal or internal organ fibrosis, is a ‘‘window 
kože i unutrašnjih organa, „prozor mogućnosti“ koji bi 
mogao biti vrijeme za intervenciju u ranoj fazi bolesti te 
time potencijalno prevenirati oštećenje organa. 
Prijedlog definicije vrlo rane SSc jest stanje obilježeno 
RP-om, difuznom oteklinom prstiju, pozitivnim protuti-
jelima specifičnima za bolest i patognomoničnim mirko-
vaskularnim promjenama vidljivima na kapilaroskopiji, a 
bez zahvaćenosti kože i unutrašnjih organa. U bolesnika 
s navedenim simptomima, radi otkrivanja pretkliničkih 
promjena na unutarašnjim organima u SSc, mogu se pro-
vesti i pretrage kao što su ezofagealna manometrija, eho-
kardiografija u B-modu i funkcijski testovi pluća. 
Nedavno su predloženi novi klasifikacijski kriteriji radi 
identificiranja bolesnika u najranijoj fazi bolesti. Me-
đutim, prediktori tijeka bolesti i dalje su nepoznati te je 
stoga potrebno redovito praćenje, iako idealna učestalost 
kontrolnih pregleda nije utvrđena. 
Ključne riječi: sustavna skleroza, rana dijagnoza, liječenje, 
klasifikacijski kriteriji, rana sustavna skleroza
Sažetak 
Sustavna skleroza (SSc) kronična je autoimuna bolest 
obilježena visokim stupnjem heterogenosti i povezana 
s visokim morbiditetom, kao i s najvišim mortalitetom 
specifičnim za samu bolest, u odnosu na sve druge autoi-
mune bolesti vezivnog tkiva. SSc moguće je jednostavno 
dijagnosticirati u uznapredovaloj fazi, dakle kad se već 
razvila obliterativna vaskulopatija te fibroza kože i unu-
trašnjih organa, ali teško je postaviti dijagnozu u ranoj 
fazi bolesti. Ta činjenica ograničuje mogućnost ranog 
liječenja i potencijalnog preveniranja razvoja bolesti i 
oštećenja tkiva. Raynaudov fenomen (engl. skr. RP) pred-
ložen je kao jedno od definirajućih kliničkih obilježja za 
dijagnozu „rane“ SSc te stoga pozornost valja poglavito 
usmjeriti na taj simptom, čak i u slučaju odsustva drugih 
znakova bolesti. Na temelju prethodnih dijagnostičkih 
kriterija dijagnoza SSc može biti postavljena nakon više 
godina od početka RP, pa i nakon pojave prvih simptoma 
nevezanih za RP. 
Ovaj je vremenski raskorak između pojave simptoma 
i postavljanja dijagnoze, ponajprije temeljen na fibrozi 
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Systemic sclerosis (SSc) is a chronic disease, characte-
rized by fibrosis of the skin and internal organs, small-
vessel vasculopathy, and immune abnormalities with 
autoantibody production. It was defined as “one of the 
most terrible of all human ills” and a “shrinking skin of 
steel” by William Osler in 1898, highlighting the deva-
stating complications affecting SSc patients. It is a hete-
rogeneous disease associated with a high morbidity and 
with the highest disease-specific mortality of all autoim-
mune connective tissue diseases (1, 2). In several studi-
es, the incidence of SSc is reported to be between 4 and 
20 new cases per 1,000,000, with a prevalence ranging 
between 30 and 450 cases per 1,000, 000 (3-5). Moreover, 
the patient’s appearance changes owing to skin sclerosis, 
muscle atrophy, and joint contracture; consequently, SSc 
also has a substantial impact on the patient’s emotional 
and psychological well-being (6, 7), resulting in loss of 
function, impairment of quality of life, and a high socio-
economic cost. This unpredictable disease still represents 
a great challenge for the rheumatologist because, despi-
te the many advances made in the understanding of the 
pathogenetic pathways and the development of new tar-
geted therapies, early diagnosis remains the weak point, 
although it is the crucial element in the management of 
SSc patients (8). Thus, it is fundamental to focus on the 
earliest signs of the disease, to look for valid predictors 
of its evolution, and to perform a close follow up of pati-
ents in order to capture the slightest change in the clinical 
condition as soon as possible. Population-based studies 
showed that mild SSc is a more frequent disease than has 
previously been suspected (9).
In fact, SSc is quite easy to diagnose in the advanced pha-
se, when characterized by an obliterative vasculopathy 
and skin and internal organ fibrosis, but diagnosis can 
be difficult in the early phases. The current classificati-
on criteria used for the diagnosis, the American College 
of Rheumatology (ACR) or LeRoy and Medsger criteria 
(10, 11), which allow only for the identification of pati-
ents with skin thickness, are thus not sensitive to early 
diagnosis of SSc when this feature is usually missing. This 
suggests that the diagnosis and, consequently, appropri-
ate treatment are delayed until skin involvement and/or 
internal organ involvement are evident (12-14), and the 
damage is probably already irreversible (9). 
Raynaud’s phenomenon (RP) is the most common initial 
symptom in many connective tissue diseases (CTDs), and 
particularly in SSc (15, 16). Despite its poor specificity, it 
has been proposed as one of the defining clinical features 
for the diagnosis of “early” SSc (10). In fact, it is conside-
red as the main sentinel sign to identify patients at higher 
risk of developing SSc. Thus great attention is devoted to 
the identification of its true diagnostic value, particular-
ly in combination with other typical early features of SSc. 
In a large prospective study, Koenig et al. showed that RP 
patients with SSc marker autoantibodies and/or typical ca-
pillaroscopic abnormalities but without any other clinical 
manifestations, are 60 times more likely to develop definite 
SSc (by ACR preliminary criteria) than other RP patients 
(17). RP may sometimes precede the onset of cutaneous 
or visceral sclerosis by decades (especially in its limited 
form), and for this reason particular attention should be 
paid to this symptom even in the absence of other signs 
of the disease. Nevertheless, based on previous diagnostic 
criteria, the diagnosis of SSc can be delayed for several ye-
ars after the onset of RP, and even after the onset of the first 
non-RP symptom.
Preliminary data from the EULAR Scleroderma Trial and 
Research group (EUSTAR) data indicate that the time gap 
between the onset of RP and the first non-RP symptom or 
sign in SSc is a mean of 4.8 years in limited cutaneous SSc 
(lcSSc) and 1.9 years in diffuse cutaneous SSc (dcSSc) (14). 
The delay between symptoms and diagnosis, mainly based 
on dermal or internal organ fibrosis, could be considered 
as a ‘‘window of opportunity’’ for these patients, allowing 
rheumatologists to intervene earlier in the disease course, 
thus potentially preventing organ damage.
To decrease the diagnostic delay, the identification of other 
earliest signs and symptoms of the disease are considered 
fundamental in the clinical practice. Today the variety of 
SSc diagnostic and classification criteria at our disposal 
enables us to identify SSc patients as early as possible, in 
order to block or slow the disease progression and reach 
an early monitor of organ-based complications.
In the past, SSc was classified and diagnosed according to 
the ACR classification criteria (1980), which required ei-
ther the presence of skin sclerosis proximal to the MCP 
or MTP joints, or the presence of two of three secondary 
criteria (sclerodactyly, digital ulcers, or lung fibrosis) (18). 
To overcome the limitations of these ACR criteria, many 
classification schemes have been developed, but all of 
them distinguish between limited cutaneous SSc (the skin 
lesions are distal to the elbows and knees +/- the face) and 
diffuse cutaneous SSc (the skin involvement is proximal to 
the elbows and knees, often including the trunk +/- face) 
(10, 11).
In 2001, Le Roy and Medsger proposed criteria for the di-
agnosis and classification of “early” SSc, including RP with 
SSc-type nailfold capillary pattern (giant capillaries and/
or avascular areas) and/or SSc specific autoantibodies (10). 
Three years later, Medsger TA jr identified early SSc as a 
disease stage that precedes the development of atrophic le-
sions and irreversible vascular occlusion in dSSc (<3 years 
from the first non-RP symptom) or lSSc (<5 years) (17). 
In 2008, early SSc patients with a high probability of deve-
loping SSc during a long-term follow up were considered 
those with RP and SSc-specific autoantibodies, or typical 
capillaroscopic abnormalities, or both (17). 
The new criteria proposed by EUSTAR (European Lea-
gue Against Rheumatism Scleroderma Trial and Research 
Group) represent a turning point in the approach to the 
diagnosis of SSc. According to these criteria, a very early 
diagnosis of SSc (VEDOSS) is suspected in the presence 
of the three red flags (RP, PF, and antinuclear antibody 
(ANA) positivity), and also if disease-specific autoantibo-
dies (anticentromere Ab (ACA) or anti-topo I Ab (Scl70)) 
or microvascular alterations are detected by nailfold vi-
deocapillaroscopy. If all of the above are present, the final 
diagnosis of VEDOSS is made. These criteria have been 
selected by a wide Delphi technique among experts on 
systemic sclerosis (18). Besides, it was shown that PF is a 
fundamental clinical criterion of the very early phase (20), 
and for this reason PF was also included in the recently 
revised ACR/EULAR classification criteria for SSc (20).
If a patient fulfills the VEDOSS criteria, further investi-
gations to assess internal organ involvement are man-
datory. In particular, esophageal manometry, B-mode 
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echocardiography, lung function tests, and esophageal 
manometry are recommended to detect preclinical altera-
tions of internal organs in SSc. 
More recently, an international ACR/EULAR collaborati-
ve initiative developed new classification criteria for SSc. 
Seven new items (including RP, puffy fingers, fingertip 
lesions, telangectasias, abnormal nailfold capillaries, SSc-
related autoantibodies, pulmonary arterial hypertension, 
and/or lung disease) were identified and weighted, and a 
provisional threshold was proposed (20). A total score of 9 
or more allows to classify a patient as affected by systemic 
sclerosis. The presence of skin thickening of the fingers of 
both hands extending proximal to the MCP joints is a suf-
ficient criterion to reach 9 points. The higher sensitivity of 
these new classification criteria in respect to the previous 
ACR criteria has been recently reported with the analysis 
of a cohort of 304 patients with early or established SSc, 
demonstrating that they classified more patients as defi-
nite SSc patients than the previous ACR criteria (21, 22). 
To highlight the importance of early diagnosis, Valentini et 
al. have shown that the internal organ involvement in SSc 
is early and subclinical, and could also be present in pati-
ents without skin involvement (23). In a high proportion 
of patients studied they reported early cardiac involvement 
with an inverted mitral E/A ratio, early lung involvement 
with a reduction of transfer factor for carbon monoxide 
(TLCO) less than 80% of the predictive value, and/or a ba-
sal lower esophageal sphincter pressure of <15mmHg (i.e., 
early esophageal involvement). These data could identify 
a subset of SSc patients who have already evolved to an 
early organ involvement and therefore might be identified 
as early rather than very early SSc. Interestingly, Lepri et 
al. found that in the very early phase an esophageal and 
anorectal involvement could also be present in SSc patients 
(24). Additionally, digital ulcers, a common vascular com-
plication in SSc, seem to be a sentinel sign for early internal 
organ involvement in very early systemic sclerosis. Since 
DUs represent a high socio-economic cost, the early detec-
tion of patients with a high risk of developing DUs could 
allow a preventive treatment, with a reduction of morbidity 
and social costs (25).
More recently, Valentini et al. have considered early SSc as 
a disease stage in which classification criteria are not yet 
satisfied, and there are different degrees of probability to 
develop the full-blown disease ranging from low to very 
high, but without absolute certainty (26). 
However, when a very early SSc diagnosis is made, there 
are two possibilities: first, the patient does not fulfill the 
ACR/EULAR criteria for SSc and should be followed up 
closely and evaluated before a treatment is chosen; second, 
the patient already fulfills the ACR/EULAR criteria for SSc 
and further investigations show an internal organ involve-
ment, thus classifying the patient as early SSc.
In conclusion, today an early diagnosis of SSc and a definite 
SSc classification are mandatory to achieve an early window 
of opportunity in order to decide whether an aggressive tre-
atment is necessary (27). As reliable predictors of the future 
course of the disease are still unknown, the patients must 
be followed up regularly, even though the ideal frequency 
of visits has not yet been established. Further studies are 
required to identify predictors of evolution that will allow us 
to understand which patients will evolve to an established 
disease with visceral involvement, in order to treat them 
promptly before internal organ damage occurs (28).
Declaration on conflict of interest: The author declares that there is no conflict of interest.
REFERENCES
1. Fett N. Scleroderma: Nomenclature, etiology, pathogenesis, 
prognosis, and treatments: Facts and controversies. Clinics in 
Dermatology. 2013;31:432–7.
2. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (sy-
stemic sclerosis): classification, subsets and pathogenesis. J 
Rheumatol. 1988;15:202. 
3. Chiffolt H. Fautrel B, Sordet C, Chateleu E, Sibilia J. Inciden-
ce and prevalence of systemic sclerosis: a systemic literature 
review . Semin Arhritis Rheum. 2008;37:223-35.
4. Mayes MD, Lacey JV, Beebe-Dimmer J, et al. Prevalence, inci-
dence, survival and disease characteristics of systemic sclero-
sis in a large US population. Arthritis Rheum. 2003;48:2246–
55.
5. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin Nor-
th Am. 2003;29:239-54.
6. Del Rosso A, Boldrini M, D’Agostino D, et al. Health-related 
quality of life in systemic sclerosis as measured by the Short 
Form 36: relationship with clinical and biologic markers. Ar-
thritis Rheum. 2004;51:475-81.
7. Valentini, Matucci Cerinic M. Disease specific quality indica-
tors, guidelines and outcome measures in scleroderma. Clin 
Exp Rheumatol. 2007;25:159-62.
8. Varga J, Abraham D. Systemic sclerosis: a prototypic multisy-
stem fibrotic disorder. J Clin Invest. 2007;117:557–67.
9. Czirjak L, Matucci-Cerinic M. Beyond Raynaud’s phenomenon 
hides very early systemic sclerosis: the assessment of organ in-
volvement is always mandatory. Rheumatology. 2011;50:250–1.
10. LeRoy EC, Medsger TA Jr. Criteria for the classification of early 
systemic sclerosis. J Rheumatol. 2001;28:1573–6.
11. Subcommittee for scleroderma criteria of the American Rhe-
umatism Association Diagnostic and Therapeutic Criteria Co-
mmittee. Preliminary criteria for the classification of systemic 
sclerosis (scleroderma). Arthritis Rheum. 1980;23:581-90.
12. Lonzetti LS, Joyal F, Raynauld JP, et al. Updating the American 
College of Rheumatology preliminary classification criteria for 
systemic sclerosis: addition of severe nailfold capillaroscopy ab-
normalities markedly increases the sensitivity for limited sclero-
derma. Arthritis Rheum. 2001;44:735–6.
13. Hudson M, Taillefer S, Steele R, et al. Improving the sensitivity 
of the American College of Rheumatology classification criteria 
for systemic sclerosis. Clin Exp Rheumatol. 2007;25:754–7.
14. Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment 
of organ manifestations in systemic sclerosis: a report from the 
EULAR Scleroderma Trials And Research group database. Ann 
Rheum Dis. 2007;66:754–63.
15. Bellando Randone S, Cutolo M, Czirjak L, Matucci Cerinic M. 
Mixed connective tissue disease, a roundabout to rheumatic di-
seases? Curr Rheumatol Rev. 2009;5:133-40.
Review paper Pregledni rad
Bellando Randone S. et al. Early scleroderma
Reumatizam 2015; Suppl 1: 62-65   65
16. Cappelli S, Bellando Randone S, Martinović D, et al. To be or not 
to be, ten years after: evidence for mixed connective tissue disea-
se as a distinct entity. Semin Arthritis Rheum. 2012;41:589-98.
17. Koenig M, Joyal F, Fritzler MJ, Roussin A, et al. Autoantibodies 
and microvascular damage are independent predictive factors 
for the progression of Raynaud’s phenomenon to systemic scle-
rosis: a twenty-year prospective study of 586 patients, with vali-
dation of proposed criteria for early systemic sclerosis. Arthritis 
Rheum. 2008;58:3902-12.
18. Avouac J, Fransen J, Walker UA, et al.; EUSTAR Group. Preli-
minary criteria for the very early diagnosis of systemic sclerosis: 
results of a Delphi Consensus Study from EULAR Scleroderma 
Trials and Research Group. Ann Rheum Dis. 2011;70:476-81.
19. Minier T, Guiducci S, Bellando-Randone S, et al.; and the EU-
STAR co-workers. Preliminary analysis of the very early diagno-
sis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: 
evidence for puffy fingers as a pivotal sign for suspicion of syste-
mic sclerosis. Ann Rheum Dis. 2014;73:2087-93.20. V a n 
den Hoogen F, Khanna D, Fransen J, et al. Classification criteria 
for systemic sclerosis: an American college of rheumatology/Eu-
ropean league against rheumatism collaborative Initiative. Ann 
Rheum Dis. 2013;72:1747-55.
21. Jordan S,  Maurer B,  Toniolo M,  Michel B,  Distler O. Per-
formance of the new ACR/EULAR classification criteria 
for  systemic sclerosis  in clinical practice. Rheumatology 
(Oxford). 2015;54:1454-8.
22. Fransen J, Johnson SR, van den Hoogen F, et al. Items for de-
veloping revised classification criteria in systemic sclerosis: 
results of a consensus exercise. Arthritis Care Res (Hoboken). 
2012;64:351–7.
23. Valentini G, Cuomo G, Abignano G et al. Early systemic scle-
rosis: assessment of clinical and preclinical organ involvement 
in patients with different disease features. Rheumatology. 
2011;50:317–23.
24. Lepri G, Guiducci S, Bellando-Randone S, et al. Evidence for 
oesophageal and anorectal involvement in very early systemic 
sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR 
centre. Ann Rheum Dis. 2015;74:124-8.
25. Bruni C, Guiducci S, Bellando-Randone S, et al. Digital ulcers as 
a sentinel sign for early internal organ involvement in very early 
systemic sclerosis. Rheumatology (Oxford). 2015;54:72-6.
26. Valentini G, Marcoccia A, Cuomo G, Iudici M, Vettori S. The 
concept of early systemic sclerosis following 2013 ACR\EULAR 
criteria for the classification of systemic sclerosis. Curr Rheuma-
tol Rev. 2014; 10:38-44.
27. Matucci-Cerinic M, Bellando-Randone S, Lepri G, Bruni C, 
Guiducci S. Very early versus early disease: the evolving defi-
nition of the many faces of Systemic Sclerosis. Ann Rheum Dis. 
2013;72:319-21.
28. Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR/EUSTAR 
recommendations for the treatment of systemic sclerosis. Ann 
Rheum Dis 2009;68:620–8.
